[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Chronic Kidney Disease (CKD) KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis Roxadustat for anemia in patients with end-stage renal disease incident to dialysis Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study Roxadustat for CKD-related Anemia in Non-dialysis Patients Anemia in Chronic Kidney Disease FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] General Upadacitinib Prescribing Information Risankizumab Prescribing Information Guselkumab Prescribing Information ACR COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases Biosimilars Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Biosimilars: implications for rheumatoid arthritis therapy. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Clinical trials of biosimilars should become more similar. Biosimilars: More Treatment Options Are on the Way FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study Gout 2022 EULAR Congress Abstract Book Pegloticase in Combination With Methotrexate in PatientsWith Uncontrolled Gout: A Multicenter, Open-label Study(MIRROR) Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients Treat to target in gout 2020 American College of Rheumatology Guideline for the Management of Gout Pegloticase Prescribing Information Pegloticase treatment of chronic refractory gout: Update on efficacy and safety Gout Patient fact Sheet Moving the Needle: Improving the Care of the Gout Patient Immune-mediated adverse reactions Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist Psoriatic Arthritis Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures Psoriatic Arthritis – Disease Primer Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 Spondyloarthritis ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update JAK1 selective inhibitors for the treatment of spondyloarthropathies Axial spondyloarthritis: new advances in diagnosis and management TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases Recognizing Axial Spondyloarthritis: A Guide for Primary Care Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? Pain in Axial Spondyloarthritis: More to It Than Just Inflammation Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities Spondylitis Association of America: Resources and Support Spondyloarthritis Patient Fact Sheet What Is Axial Spondyloarthritis (AxSpA)? Recommendations for the Treatment of Ankylosing Spondylitis 2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial Juvenile Idiopathic Arthritis (JIA) ACR Update of Recommendations to the Treatment of JIA What is JIA? - Patient Handout Lupus Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors Update on lupus epidemiology: advancing health disparities research through the study of minority populations Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus Trial of Anifrolumab in Active Systemic Lupus Erythematosus 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Lupus Foundation of American Caregiver Toolkit Patient Fact Sheet: Lupus Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments Phase 3 AURORA study of voclosporin versus standard of care in lupus nephritis Belimumab prescribing information Voclosporin prescribing information Rheumatoid Arthritis (RA) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis RA and Vaccinations RA Treat-to-Target Recommendations The Purple Book for Biosimilars RA Overview (for Patients) RA Treatment (for Patients) <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fbiosimilars%2Fpatient-materials&data=04%7C01%7Ctallvord%40vindicocme.com%7Cddf22154d15e4464ab4608d9fe07aaa7%7Cda938b042dd64bbcbe65f6c4645153a1%7C0%7C0%7C637820131145774579%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=drUGr3mVPmqfXdFR1nDwskxvKRiJvkNR9o9xZP17r8s%3D&reserved=0" target="_blank" rel="noopener noreferrer">FDA Information on Biosimilars (for Patients) RA Overview (for Patients) RA Treatment (for Patients) Systemic Sclerosis Understanding Scleroderma: National Scleroderma Foundation Patient Education 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Interstitial lung disease associated with systemic sclerosis (SSc-ILD) Vasculitis ANCA-Associated Vasculitis 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis ANCA-Associated Vasculitis EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis American College of Rheumatology Churg-Strauss Syndrome Classification Criteria National Organization for Rare Disorders: Churg Strauss Syndrome Eosinophilic Granulomatosis With Polyangiitis (EGPA) Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis American College of Rheumatology Churg-Strauss Syndrome Classification Criteria National Organization for Rare Disorders: Churg Strauss Syndrome Giant Cell Arteritis Giant Cell Arteritis – Fast Facts for Patients Giant Cell Arteritis – Vasculitis Foundation ACR Classification of Giant Cell Arteritis GIACTA Trial of Tocilizumab in Giant Cell Arteritis Giant Cell Arteritis [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Interstitial Lung Disease (ILD): Idiopathic Pulmonary Fibrosis (IPF) Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline European Respiratory Society/ American Thoracic Society Walking Test Guidelines Pulmonary Fibrosis Foundation Educational Resources <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2008470" target="_blank" rel="noopener noreferrer">Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00165-X/fulltext" target="_blank" rel="noopener noreferrer">Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journal.chestnet.org/article/S0012-3692(20)30872-2/fulltext" target="_blank" rel="noopener noreferrer">The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung DiseaseDilemmas in Diagnosis and the Conundrum of Treatment <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/co-pulmonarymedicine/Abstract/2021/09000/Pulmonary_hypertension_in_interstitial_lung.16.aspx" target="_blank" rel="noopener noreferrer">Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/article/10.1007/s41030-019-00105-5" target="_blank" rel="noopener noreferrer">Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.jhltonline.org/article/S1053-2498(21)02178-1/fulltext" target="_blank" rel="noopener noreferrer">Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.jhltonline.org/article/S1053-2498(21)02178-1/fulltext" target="_blank" rel="noopener noreferrer">A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis Inhaled Treprostinil: Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://thorax.bmj.com/content/71/5/429.full.pdf+html" target="_blank" rel="noopener noreferrer">Effect of continued treatment with pirfenidone (Nathan SD, et al. Thorax. 2016;71:429-435.) <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205832s012lbl.pdf" target="_blank" rel="noopener noreferrer">Nintedanib Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf" target="_blank" rel="noopener noreferrer">Pirfenidone Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.atsjournals.org/doi/full/10.1164/rccm.202005-2032ST" target="_blank" rel="noopener noreferrer">Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.atsjournals.org/doi/full/10.1164/rccm.201807-1255ST" target="_blank" rel="noopener noreferrer">Diagnosis of IPF: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.pulmonaryfibrosis.org/life-with-pf/pff-educational-resources/patient-education-materials" target="_blank" rel="noopener noreferrer">Pulmonary Fibrosis Foundation Patient Education Materials <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30341-8/fulltext" target="_blank" rel="noopener noreferrer">Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.atsjournals.org/doi/10.1513/AnnalsATS.201810-720RL" target="_blank" rel="noopener noreferrer">Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30326-5/fulltext" target="_blank" rel="noopener noreferrer">Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30059-1/fulltext" target="_blank" rel="noopener noreferrer">Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.atsjournals.org/doi/10.1164/rccm.202003-0877OC" target="_blank" rel="noopener noreferrer">Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30036-9/fulltext" target="_blank" rel="noopener noreferrer">Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://bmjopenrespres.bmj.com/content/6/1/e000397" target="_blank" rel="noopener noreferrer">Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials Interstitial Lung Disease (ILD): Sarcoidosis ERS clinical practice guidelines on treatment of sarcoidosis Repository corticotropin for Chronic Pulmonary Sarcoidosis Non-Tuberculous Mycobacteria Learn about NTM Lung Disease ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Inhaled Antibiotic Therapy in Chronic Respiratory Diseases “INSIGHT” A Patient’s Perspective on NTM CDC Clinician Resources on NTM Infection Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Binge Eating Disorder (BED) Definition & Facts for Binge Eating Disorder – NIH Patient Education Weight Stigma in the Practice of Psychotherapy for Binge Eating Disorder: Guidance for Professionals Weight Stigma in Kids’ Programs and Schools: Guidance for Kids’ Programs Leaders DSM-5 Criteria for Binge Eating Disorder NOTE: This tool is best viewed in Google Chrome or Internet Explorer Binge Eating Disorder (BED) - A Comorbid Conundrum Binge Eating Disorder Resources Bipolar Disorder Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial Evaluating lurasidone as a treatment option for bipolar disorder Bipolar Disorder Diagnosis and Treatment for Patients Treatment of Bipolar Depression in Children and Adolescents Understanding Bipolar Depression - Patient Handout Depression BPRS Brief Psychiatric Rating Scale PHQ-9 Quick Depression Assessment Montgomery-Asberg Depression Rating Scale Edinburgh Postnatal Depression Scale Depression - stopping your medicine – Patient Handout Major Depressive Disorder – Patient Handout What are the Causes of Depression? - Patient Handout Mood Disorders Protocol for the Treatment of Agitation Parkinson’s Disease Psychosis QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment Schizophrenia Emerging Treatments in Schizophrenia Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities Xanomeline–Trospium for Schizophrenia Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia New Second-generation Antipsychotics Long-acting Injectable Second Generation Antipsychotics Examples of Neurocognitive Assessments that Can Be Completed at the Bedside Motivational Interviewing: A tool to improve medication adherence? Living with Schizophrenia - Patient Handout Antipsychotics Fact Sheet - Patient Handout Support Groups and Supportive Resources - Patient Handout Approach to Schizophrenia Management At-A-Glance - Patient Handout Schizophrenia: Recognizing the Symptoms and Getting Treatment - Patient Handout Substance Use Disorders Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Opioid Treatment Program (OTP) Certification Medication Assisted Treatment (MAT) Certification Tardive Dyskinesia (TD) Abnormal Involuntary Movement Scale exam Tardive Dyskinesia for Patients and Families Valbenazine Prescribing Information Deutetrabenazine Prescribing Information [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Biosimilars State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Pharmacist Substitution of Biological Products: Issues and Considerations

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Anesthesia Statement on Practice Recommendations for Pediatric Anesthesia Sugammadex and recurarization in an infant Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study Sugammadex: Applications in Pediatric Critical Care Association Between a Single General Anesthesia Exposure Before Age 36 Months and Neurocognitive Outcomes in Later Childhood Neurodevelopmental outcome at two years of age after general and awake-regional anaesthesia in infancy: a randomized controlled trial Smart Tots Ear, Nose and Throat Conditions Improving the Diagnosis of Acute Otitis Media: “Seeing Is Believing” Clinical Practice Guideline: Tympanostomy Tubes in Children Tympanostomy Tube Placement in Children Using a Single-Pass Tool with Moderate Sedation Hummingbird TTS. Instructions for Use Ear Tubes in Pediatric Patients: Get the Facts – Educational Tool for Parents Gastroenterology Persistent Diarrhea: A Clinical Review Cryptosporidiosis Giardiasis For Parents: Treating Pediatric Dehydration Swimming Pool Hygiene Children’s Health GI Kids MRI with gadolinium contrast media FDA Drug Safety Communication: Gadolinium-based contrast agents for MRIs Information on Gadolinium-Based Contrast Agents NIH Perspective on Reports of Gadolinium Deposition in the Brain American Guidelines ACR/ASNR Position Statement on Use of Gadolinium Contrast Agents Psychiatry CDC what is ADHD? Symptoms and Diagnosis of ADHD Vaccine-preventable Diseases: General Pediatric Vaccination – Information for Parents Vaccine-preventable Diseases: Influenza Flu: A Guide for Parents Frequently Asked Influenza (Flu) Questions: 2022-2023 Season No More Excuses: You Need a Flu Vaccine Make a Strong Influenza Vaccine Recommendation Influenza Activity and Composition of the 2022–23 Influenza Vaccine — United States, 2021–22 Season Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season - ScienceDirect Recommendations for Prevention and Control of Influenza in Children, 2022-2023 Recommendations for Prevention and Control of Influenza in Children, 2022–2023 Vaccine-preventable Diseases: Human Papillomavirus (HPV) HPV vaccine promotion: Snapshot of two health departments during the COVID-19 pandemic Understanding primary care physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy Addressing HPV vaccine myths: practical information for healthcare providers Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial Top 10 Tips for HPV Vaccination Success CDC: ACIP’s HPV Vaccination Recommendations CDC: Talking to Parents about HPV Vaccine Pediatric Vaccination – Information for Parents CDC Resources, Education & References for HPV Vaccination Human Papillomavirus Vaccination: ACOG Committee Opinion Vaccination Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men Gardasil 9 Expanded for Patients Aged 27-45 Years Old HPV Vaccination: What Everyone Should Know CDC HPV Vaccine Recommendations Standing Order for HPV Vaccine Centers for Disease Control and Prevention HPV Vaccine Recommendations Recommended Immunization Schedule for Persons Aged 0 Through 18 Years (United States, 2017) – Educational Tool for Clinicians and Nurses Why Are Childhood Vaccines So Important? – Educational Tool for Parents [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Characteristic Types of Pain Following Total Knee Arthroplasty Diagnostic Algorithm for the Assessment of Patients Suffering from Pain Following Total Knee Arthroplasty Pain Management CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 Substance Use Disorders Medication-Assisted Treatment Using Buprenorphine [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Age-Related Macular Degeneration (AMD) Port delivery system with ranibizumab (Susvimo) recall: What does it mean to the retina specialists FDA approves the Port Delivery System (PDS) with ranibizumab for treatment of wet AMD Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema Suprachoroidal Delivery of RGX-314 Well-Tolerated in Wet AMD FDA approves faricimab for treatment of wet AMD, DME TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Port delivery system: a novel drug delivery platform to treat retinal diseases Review of gene therapies for age-related macular degeneration. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice Faricimab shows efficacy, safety and durability in treatment of wet AMD Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration Abicipar pegol—a novel anti-VEGF therapy with a long duration of action <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biospace.com%2Farticle%2Freleases%2Fport-delivery-system-with-ranibizumab-shows-positive-phase-iii-results-in-neovascular-age-related-macular-degeneration-%2F&data=04%7C01%7Ctallvord%40vindicocme.com%7Ce7a3d7397f86489d9a0708d9bf126a88%7Cda938b042dd64bbcbe65f6c4645153a1%7C0%7C0%7C637750908164102540%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=dQUE1DKBzxpzEUgYF%2F5s2%2BW7D0ZMenLX49IRQFsp%2FxI%3D&reserved=0" target="_blank" rel="noopener noreferrer">Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration Use and Safety of brolucizumab Intravitreal Aflibercept for AMD: 2-year Results What AREDS means for you? Addressing the Anti-VEGF Treatment Burden ICD-10 Decision Tree: AMD Mayo Clinic: Dry Macular Degeneration American Academy of Ophthalmology Preferred Practice Patterns for AMD Understanding Your AMD - Patient Handout Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration - Patient Handout Research progress about the effect and prevention of blue light on eyes The Good and Bad of Retinal Fluid Review of Neovascular Age-Related Macular Degeneration Treatment Options Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. Results from the Randomized Phase 2 Ladder Clinical Trial Results from the Phase 3 HAWK and HARRIER Studies Faricimab Demonstrates Durable Ang-2, VEGF Suppression Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration Cataract and/or Refractive Surgery Latest Development in Extended Depth-of-Focus Intraocular Lenses: An Update AAO Cataract in the Adult Eye Preferred Practice Pattern 2021 Intraoperative and postoperative pain in cataract surgery Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery Does Cataract Surgery Hurt? Strategies for Preventing Intraoperative Miosis Cataract and Refractive Lens Exchange Questionnaire Post-Refractive IOL Calculator American Academy of Ophthalmology Task Force Consensus Statement for Extended Depth of Focus Intraocular Lenses American Society of Cataract and Refractive Surgery Physician Quality Reporting System Measures Associated with Cataract Surgery Toric IOL Calculator Preparing for Cataract Surgery - Postoperative Concerns - Patient Handout Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery Conjunctivitis Conjunctivitis (Pink Eye) Treatment Conjunctivitis: What is Pink Eye? – Patient Information Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout Diabetic Macular Edema (DME) Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393252/" target="_blank" rel="noopener noreferrer">The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema: The European DME Registry Study Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema The Mechanism of the Bispecific Antibody Faricimab Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout American Optometric Association Evidence-Based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial Facts About Macular Edema 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States Diabetic Retinopathy Diabetic Retinopathy: Are You Being Screened? (for Patients) Retina Summary Benchmarks, 2021 (for Patients) What Is Diabetic Retinopathy? Understanding Diabetic Retinopathy – Patient Handout Diabetic Retinopathy Clinical Research Network Publications Diabetic Retinopathy: Causes, Symptoms, Treatment ICD-10 Decision Tree: Diabetes Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial Early intervention with Aflibercept has positive results in PANORAMA trial Digital Algorithmic Diabetic Retinopathy Severity Scoring System (An American Ophthalmological Society Thesis) Early intervention with Afilbercept has positive results in PANORAMA trial What’s Next for Bispecific Antibody Faricimab PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy Geographic Atrophy Understanding Geographic Atrophy in Advanced Non-Exudative Age-Related Macular Degeneration: a Teaching Case Report Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy Patient Perspectives in Geographic Atrophy (GA): Exploratory Qualitative Research to Understand the Impact of GA for Patients and Their Families Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration Prevalence and phenotype associations of complement factor I mutations in geographic atrophy Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial General ICD-10-CM for Ophthalmology EyeNet Magazine National Institutes of Health Guidelines on Human Subjects Research Eye Health Tips - Patient Handout AAO Preferred Practice Patterns American Academy of Ophthalmology. Teleophthalmology: how to get started. Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet. Vicchrilli S. Savvy coder: telemedicine during the public health emergency. AAO.org: Home Eye Test for Adults Glaucoma CDC Vision Health Initiative: Facts About Glaucoma ICD-10 Glaucoma Reference Guide <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.liebertpub.com/doi/epdf/10.1089/jop.2022.0137" target="_blank" rel="noopener noreferrer">Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/article/10.1007%2Fs00417-021-05410-x" target="_blank" rel="noopener noreferrer">The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1901222" target="_blank" rel="noopener noreferrer">A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.liebertpub.com/doi/10.1089/jop.2020.0112?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&" target="_blank" rel="noopener noreferrer">Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma" target="_blank" rel="noopener noreferrer">National Eye Institute: Glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/co-ophthalmology/Abstract/2021/03000/Advances_in_medical_therapy_for_glaucoma.8.aspx" target="_blank" rel="noopener noreferrer">Advances in medical therapy for glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nature.com/articles/s41433-019-0671-0.pdf" target="_blank" rel="noopener noreferrer">New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/article/10.1007%2Fs12325-020-01277-2" target="_blank" rel="noopener noreferrer">Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://bjo.bmj.com/content/bjophthalmol/early/2021/02/04/bjophthalmol-2020-317262.full.pdf" target="_blank" rel="noopener noreferrer">Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/glaucomajournal/Abstract/9000/2_Year_Experience_with_Latanoprostene_Bunod_in.97544.aspx" target="_blank" rel="noopener noreferrer">2 Year Experience with Latanoprostene Bunod in Clinical Practice <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790669/pdf/ijo-14-01-148.pdf" target="_blank" rel="noopener noreferrer">Sustained-release drug delivery systems for the treatment of glaucoma Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30489-7/fulltext" target="_blank" rel="noopener noreferrer">Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1901222" target="_blank" rel="noopener noreferrer">A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.liebertpub.com/doi/10.1089/jop.2020.0112?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&" target="_blank" rel="noopener noreferrer">Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/co-ophthalmology/Abstract/2021/03000/Advances_in_medical_therapy_for_glaucoma.8.aspx">Advances in medical therapy for glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nature.com/articles/s41433-019-0671-0.pdf" target="_blank" rel="noopener noreferrer">New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/article/10.1007%2Fs12325-020-01277-2" target="_blank" rel="noopener noreferrer">Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://bjo.bmj.com/content/bjophthalmol/early/2021/02/04/bjophthalmol-2020-317262.full.pdf" target="_blank" rel="noopener noreferrer">Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/glaucomajournal/Abstract/9000/2_Year_Experience_with_Latanoprostene_Bunod_in.97544.aspx" target="_blank" rel="noopener noreferrer">2 Year Experience with Latanoprostene Bunod in Clinical Practice <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nicox.com/assets/files/Weinreb-J-Glaucoma-2018-Pooled-phase-3.pdf" target="_blank" rel="noopener noreferrer">Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://ascrs.confex.com/ascrs/20am/meetingapp.cgi/Paper/64585" target="_blank" rel="noopener noreferrer">Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://journals.lww.com/co-ophthalmology/Abstract/2021/03000/Advances_in_medical_therapy_for_glaucoma.8.aspx" target="_blank" rel="noopener noreferrer">Advances in medical therapy for glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nature.com/articles/s41433-019-0671-0.pdf" target="_blank" rel="noopener noreferrer">New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/article/10.1007%2Fs12325-020-01277-2" target="_blank" rel="noopener noreferrer">Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2 <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://bjo.bmj.com/content/bjophthalmol/early/2021/02/04/bjophthalmol-2020-317262.full.pdf" target="_blank" rel="noopener noreferrer">Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.aaojournal.org/action/showPdf?pii=S0161-6420%2820%2930555-8" target="_blank" rel="noopener noreferrer">Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211911s000lbl.pdf" target="_blank" rel="noopener noreferrer">Bimatoprost Implant. Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208259s000lbl.pdf" target="_blank" rel="noopener noreferrer">Netarsudil and Latanoprost Ophthalmic Solution Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693832/" target="_blank" rel="noopener noreferrer">A Review of Nitric Oxide for the Treatment of Glaucomatous Disease <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://link.springer.com/book/10.1007%2F978-1-4614-8348-9" target="_blank" rel="noopener noreferrer">Surgical Innovations in Glaucoma <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://eyewiki.aao.org/Microinvasive_Glaucoma_Surgery_(MIGS)" target="_blank" rel="noopener noreferrer">Microinvasive Glaucoma Surgery (MIGS) <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/labeling/xen/dfu_xen_glaucoma_treatment_system_us_feb2017.pdf" target="_blank" rel="noopener noreferrer">Xen Gel Stent: Directions for Use <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf" target="_blank" rel="noopener noreferrer">Netarsudil Prescribing Information <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf" target="_blank" rel="noopener noreferrer">Latanoprostene Bunod Prescribing Information American Glaucoma Society <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://m1.healio.com/~/media/vme-educational-tools/ophthalmology/patient_ophth_dont-lose-sight-of-glaucoma.pdf" target="_blank" rel="noopener">Don't Lose Sight of Glaucoma - Patient Handout <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://m3.healio.com/~/media/vme-educational-tools/ophthalmology/patient_ophth_needtoknowglaucoma.pdf" target="_blank" rel="noopener">What You Need to Know About Glaucoma - Patient Handout <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="/Users/scooper/Downloads/BC-3867%20Update%20ICD-10%20Quick%20Reference%20Guides%20for%202020_Glaucoma_final_color.pdf" target="_blank" rel="noopener noreferrer">ICD-10 Glaucoma Reference Guide <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nei.nih.gov/sites/default/files/2019-06/Facts-about-glaucoma.pdf" target="_blank" rel="noopener noreferrer">Facts About Glaucoma Inherited Retinal Diseases Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium Genetic testing and diagnosis of inherited retinal diseases Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations - 2022 Genetic Testing for Inherited Retinal Disease Gene therapy for the treatment of X-linked retinitis pigmentosa Genetic testing for inherited retinal degenerations: Triumphs and tribulations Patient Information – Inherited Retinal Diseases Foundation Fighting Blindness Macular Disorders Management Recommendations for Macular Hole Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface Understanding Vitreomacular Traction Syndrome - Patient Handout Managing Challenging Macular Holes Neurotrophic Keratitis Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease? Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment. Neurotrophic Keratitis: Early Intervention is Key Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis Neurotrophic keratopathy: current challenges and future prospects Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease? Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis Neurotrophic keratopathy: current challenges and future prospects Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy Diagnosis and management of neurotrophic keratitis Cenegermin: A Review in Neurotrophic Keratitis Neuromyelitis Optica Spectrum Disorder (NMOSD) Contemporary management challenges in seropositive NMOSD Guthy Jackson Foundation Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in NMOSD Long-term efficacy and safety of inebilizumab in NMOSD: Analysis of AQP4-IgG seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder (SAkuraStar) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Neuromyelitis Optica Spectrum Disorder The Sumaira Foundation for NMO Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder Ocular Surface and Lid Margin Disease Meibomian gland disease: the role of gland dysfunction in dry eye disease A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review Racial and Ethnic Disparities in Dry Eye Diagnosis and Care Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials AAO EyeWiki: Meibomian Gland Dysfunction (MGD) NIH Dry Eye Patient Information Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease Meibomian gland disease: the role of gland dysfunction in dry eye disease A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1) Demodex Blepharitis: Clinical Perspectives Demodex and Eye Disease A Clinical Scoring System for Diagnosis of Ocular Demodicosis Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study Emerging therapies for dry eye disease AAO: Improved Dry Eye Drugs for 2022 and Beyond The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares New strategies for the management of ocular surface disease in glaucoma patients <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dovepress.com%2Fphase-3-efficacy-worse-eye-analysis-and-long-term-safety-evaluation-of-peer-reviewed-fulltext-article-OPTH&data=04%7C01%7C%7C81de8ba858684e07ec1108d91632feff%7Cda938b042dd64bbcbe65f6c4645153a1%7C0%7C0%7C637565230543199480%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=PGiWo06NmWo2Bh0MQtU468HVvlL7VGbdmLbk%2F2mJ5Tg%3D&reserved=0" target="_blank" rel="noopener noreferrer">Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies Neurostimulation in dry eye disease-past, present, and future <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dovepress.com%2Fcomparison-of-the-ilux-and-the-lipiflow-for-the-treatment-of-meibomian-peer-reviewed-fulltext-article-OPTH&data=04%7C01%7C%7C81de8ba858684e07ec1108d91632feff%7Cda938b042dd64bbcbe65f6c4645153a1%7C0%7C0%7C637565230543209477%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=gVFt7Sk531dlucW%2BS6gDXLI8AgT60vZ1VXE3QkSFEHo%3D&reserved=0" target="_blank" rel="noopener noreferrer">Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis Diseases of Ocular Surface Dry Eye: Patient Information TFOS DEWS II Definition and Classification Report American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome Care of the Patient with Ocular Surface Disorders American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis Sjögren’s Syndrome Foundation Presbyopia Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment Review of Presbyopia Treatment with Corneal Inlays and New Developments Safety and Efficacy of AGN-190584 in Individuals With Presbyopia The GEMINI 1 Phase 3 Randomized Clinical Trial 1.25% Pilocarpine for Presbyopia Potential new presbyopia treatments in development What Is Presbyopia? (Patient Material) Presbyopia Treatment (Patient Material) A Review of Pharmacological Presbyopia Treatment Treatments for presbyopia coming soon Retinal Vascular Diseases (RVO) Wide-field angiography in retinal vein occlusions Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser Five-year outcomes of retinal veinocclusion treated with vascularendothelial growth factor inhibitors Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry Branch Retinal Vein Occlusion Information for Patients Central Retinal Vein Occlusion Information for Patients ICD-10 Decision Tree: Vein Occlusion Understanding Your Retinal Vein Occlusion (RVO) - Patient Handout Retinal Vein Occlusions Preferred Practice Patterns Thyroid Eye Disease (TED) Patient Brochures Navigating the New Treatment Landscape Graves’ Eye Disease: Patient Information from the American Thyroid Association Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment OPTIC-X Study <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359449/" target="_blank" rel="noopener noreferrer">Future Projections in Thyroid Eye Disease Patient Material: Examining the Optics of TED Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease Therapeutic IGF-I receptor inhibition alters fibrocyteimmune phenotype in thyroid-associated ophthalmopathy Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease Teprotumumab for patients with active thyroid eye disease: pooled data analysis, subgroup analyses, andoff-treatment follow-up results Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists Audiology findings in patients with teprotumumab associated otologic symptoms Graves’ Ophthalmopathy Review Article: Graves’ Disease Graves' Disease: Patient Information Teprotumumab for the Treatment of Active Thyroid Eye Disease Uveitis Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Preparing for Your Appointment - Patient Handout Uveitis Guidelines: Immunomodulatory Therapy Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis MUST Study 7-Year Results Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III Vitreoretinal Surgery Avoiding and Managing Complications of Vitreoretinal Procedures Preparing for a Vitrectomy - Patient Handout Advances in Vitreoretinal Surgery [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Internet Tracking Tools for the Bariatric Patient CDC: Healthy Weight, Nutrition, and Physical Activity—Planning Meals Who’s Who on the Obesity Care Team – Patient Education 2023 Consensus Statement on Obesity Weight Bias in Healthcare: A Guide for Healthcare Providers Working with Individuals Affected by Obesity Curated Resources for the Management of Obesity in the Primary Care Setting Guide for the Management of Obesity in the Primary Care Setting Physical Activity Guidelines for Americans Prescription Medications to Treat Overweight and Obesity Bariatric Surgery: Patient Materials 2021 Obesity Algorithm® The Genetics of Human Obesity STOP Obesity Alliance - WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients Neurobiology of food intake in health and disease Management of Obesity Internet Tracking Tools for the Bariatric Patient Some Myths about Nutrition & Physical Activity American Board of Obesity Medicine (ABOM) Complementary and Alternative Medicine for the Treatment of Obesity AHA/ACC/TOS Treatment Algorithm - Chronic Disease Management Model for Primary Care of Patients with Overweight and Obesity How To Manage Your Weight Without Being Hungry - Patient Handout How To Use Fruits and Vegetables - Patient Handout How To Avoid Portion Size Pitfalls To Help Manage Your Weight - Patient Handout Rethink Your Drink - Patient Materials Childhood Obesity Facts [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" min_height="" link="" background_blend_mode="overlay" first="true"][fusion_text] Alzheimer’s Disease Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease Aducanumab: evidence from clinical trial data and controversies Aducanumab produced a clinically meaningful benefit in association with amyloid lowering FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment 2022 Alzheimer’s Disease Facts and Figures Alzheimer’s Disease Fact Sheet NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Alzheimer’s disease drug development pipeline: 2020 Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data Amyotrophic Lateral Sclerosis NIH Amyotrophic Lateral Sclerosis Fact Sheet Edaravone Prescribing Information ALS Association Migraine Frequently Asked Questions About Migraine Symptoms Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View Atogepant for the Preventive Treatment of Migraine Multiple Sclerosis (MS) Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs) MS, COVID-19 and vaccines – updated global advice Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis Shared decision-making in multiple sclerosis Shared Decision-Making in Multiple Sclerosis Management The SHARE Approach: Essential Steps of Shared Decision making: Expanded Reference Guide with Sample Conversation Starters Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis The Use of Disease-Modifying Therapies in MS Adherence — Patient Information Resources for You and Your Practice Mobile Applications for People with Multiple Sclerosis (MS) Pregnancy and Reproductive Issues Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis Disease-modifying Therapies for MS Muscular Dystrophy Limb-girdle muscular dystrophy Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion Parkinson's Disease Parkinson’s Disease Fact Sheet The On-Off Phenomenon On-Off Phenomenon: When Levodopa Stops Working as Well Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.tandfonline.com/doi/full/10.1080/24748706.2021.1907639?scroll=top&needAccess=true" target="_blank" rel="noopener noreferrer">Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://jamanetwork.com/journals/jama/article-abstract/2787115" target="_blank" rel="noopener noreferrer">Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.027123" target="_blank" rel="noopener noreferrer">Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://m3.healio.com/~/media/vme-educational-tools/neurology/a-patient-guide-to-understanding-strokes-of-unknown-cause-pdf-ucm477655.pdf" target="_blank" rel="noopener">A Patient Guide to Understanding Strokes of Unknown Cause <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://m3.healio.com/~/media/vme-educational-tools/neurology/crytopgenic-professional-guide-ucm-477051.pdf" target="_blank" rel="noopener">2019 Updated Healthcare Professional Guide Understanding Diagnosis and Treatment of Cryptogenic Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1610057" target="_blank" rel="noopener noreferrer">RESPECT Trial- Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707404" target="_blank" rel="noopener noreferrer">REDUCE Trial- Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508290/pdf/nihms411785.pdf" target="_blank" rel="noopener noreferrer">Reducing Door-to-Needle Times using Lean Principles Implementation of Telemedicine Within Stroke Systems of Care <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://stroke.ahajournals.org/content/early/2015/12/22/STR.0000000000000086.full.pdf+html" target="_blank" rel="noopener noreferrer">Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.annemergmed.com/article/S0196-0644(15)00576-4/pdf" target="_blank" rel="noopener noreferrer">Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://stroke.ahajournals.org/content/39/9/2637.long" target="_blank" rel="noopener noreferrer">Optimizing Stroke Systems of Care <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://stroke.ahajournals.org/content/45/6/1876.long" target="_blank" rel="noopener noreferrer">Effect of Telestroke on Emergent Stroke Care and Outcomes TeleStroke Simulation Video Know the Signs and Symptoms of a Stroke - Patient Handout <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://stroke.ahajournals.org/content/early/2014/10/28/STR.0000000000000046.full.pdf+html" target="_blank" rel="noopener noreferrer">American Heart Association / American Stroke Association Guidelines for the Primary Prevention of Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="http://www.stroke.org/understand-stroke/recognizing-stroke/act-fast" target="_blank" rel="noopener noreferrer">Recognize Warning Signs of a Stroke (Act FAST) <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://jamanetwork.com/journals/jamaneurology/article-abstract/2763602" target="_blank" rel="noopener noreferrer">Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.aan.com/Guidelines/home/GuidelineDetail/991" target="_blank" rel="noopener noreferrer">American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nejm.org/doi/full/10.1056/NEJMc2033779" target="_blank" rel="noopener noreferrer">REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.nejm.org/doi/full/10.1056/nejmoa1705915" target="_blank" rel="noopener noreferrer">CLOSE trial: Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Skip to content

Home
Capabilities
Our Team
Careers
News
Resources

FAQs

0

12 Next

For General inquiries, contact:
[email protected]

For Technical questions, contact:
[email protected]VindicoCME .com

For CME questions, contact:
[email protected]VindicoCME .com

Corporate Office
Vindico Medical Education
6900 Grove Road
Building 100
Thorofare, NJ 08086-9447 USA

Phone: 888-960-0256; 856-994-9400
FAX: 856-384-6680

Tweets byVindicoMedEd

vindico_live

Happy #MatchDay! Congratulations & continued succe

🍀It’s your lucky day! Earn #CME credits with

Thanks to our fantastic faculty for a great CME lu

Today and every day, we celebrate women's achievem

Join us during #NANOS2023! Links in bio for more i

That’s a wrap for Lipid Forum® 2023!

#TellingItLikeItIs was a success ✅ #Optha $#TellingItLikeItIs was a success ✅ #OpthalmologyEducation #CME #DryEyeDisease #DryEyeEducation #RefractiveSurgery #CorneaEducation #SurgeonEducators$

Missed the first webinar? Don't miss your last cha

You'll LOVE these #CME credits! Stay up to date on

Celebrate #WorldRadioDay with this 6-part #CME pod

Kick off your Sunday with this #SuperCME activity!

Congratulations to our very own, Katie Robinson, P

🌺🌴 That's a wrap for #HawaiianEye2023 ! Th

Punxsutawney Phil saw his shadow, which means #Six

Happy Friday! Closing out January with our first q

Check out this quick video to learn more about Vin

Wednesday check in from #HawaiianEye

Special shoutout to all of our Vindico staff curre

A Sunday well spent in Hawaii 🌺🌊☀️ #Haw